Recombinant Human Arylsulfatase A (rhASA, ( DrugBank: - )


1 disease
告示番号疾患名(ページ内リンク)臨床試験数
19ライソゾーム病2

19. ライソゾーム病


臨床試験数 : 899 薬物数 : 684 - (DrugBank : 99) / 標的遺伝子数 : 51 - 標的パスウェイ数 : 182
No.TrialIDDate_
enrollment
Date_
registration
Public_titleScientific_titleConditionInterventionPrimary_
sponsor
Secondary_
sponsor
Recruitment_
Status
Inclusion_
agemin
Inclusion_
agemax
Inclusion_
gender
Target_
size
PhaseCountries
1EUCTR2011-002044-28-DE
(EUCTR)
14/06/201228/06/2011A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injectionA Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy Treatment of Metachromatic Leukodystrophy
MedDRA version: 19.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Code: HGT-1110
INN or Proposed INN: N/A
Other descriptive name: Recombinant Human Arylsulfatase A (rhASA,
Shire Human Genetics Therapies IncNULLNot RecruitingFemale: yes
Male: yes
24Phase 1;Phase 2France;Brazil;Denmark;Australia;Germany;Japan
2EUCTR2011-002044-28-DK
(EUCTR)
25/11/201116/08/2011A safety and efficacy study in Children with Metachromatic Leukodystrophy recieving enzyme (HGT-1110) replacement by intrathecal injectionA Phase I/II, Multicenter, Open-label, Dose Escalation Study of HGT-1110 Administered Intrathecally in Children with Metachromatic Leukodystrophy Treatment of Metachromatic Leukodystrophy
MedDRA version: 19.0;Level: PT;Classification code 10067609;Term: Metachromatic leukodystrophy;System Organ Class: 10010331 - Congenital, familial and genetic disorders;Therapeutic area: Body processes [G] - Genetic Phenomena [G05]
Product Code: HGT-1110
INN or Proposed INN: N/A
Other descriptive name: Recombinant Human Arylsulfatase A (rhASA,
Shire Human Genetics Therapies IncNULLNot RecruitingFemale: yes
Male: yes
24Phase 1;Phase 2France;Brazil;Australia;Denmark;Germany;Japan